Benign Prostatic Hyperplasia Treatment Devices Market to Witness the Highest Growth Globally in Coming Years

Benign Prostatic Hyperplasia (BPH) refers to an enlarged prostate gland. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Enlargement of prostate gland leads to blockage in urethra, thus causing problems during urination. It involves glandular and stromal epithelial hyperplasia, which occurs in the peri-urethral transition zone surrounding the urethra.

BPH is common in aging men, and about half of all men between the age of 51 to 60 years suffer from BPH. The global BPH treatment devices market is expected to increase in the forecast period (2017-2023) due to increasing aging population, rising prevalence of BPH, increasing awareness about BPH procedures and surge in adoption of minimally invasive procedures. BPH treatment includes Transurethral microwave thermotherapy (TUMT), Transurethral needle ablation (TUNA), Transurethral resection of the prostate (TURP), Transurethral incision of the prostate (TUIP), Laser surgery, Prostatic implants and Other procedures. The BPH treatment devices market is segmented on the basis of procedure type and end user.

Request to Get the Sample Pages at:

According to the United Nations Department of Economic and Social Affairs (UNDESA), reports on the global aging population, the number of people aged 60 years or above is growing at a high rate and is projected to grow by 56.0 % globally, i.e. from 901 million in 2015 to 1.4 billion by 2030, and is projected to more than double its size from 2015, to reach 2.1 billion, by 2050. According to the National Institute of Health, it has been estimated that around 14 million men in the U.S. had symptoms suggestive of BPH, which can affect 50% of men aged between 51 and 60 years of age, and up to 90% of men aged more than 80 years. With 50% of men getting affected with BPH, there is a consequent increase in the BPH treatment devices.

Make Enquiry Before Buying the Report:

North America accounted for the largest share in the BPH treatment devices market in 2016, due to the rising prevalence of benign prostatic hyperplasia, rising aging population, and spur in healthcare expenditure. Partnerships between public and private sectors for the development of low-cost medical devices, and favorable reimbursement policies are also likely to drive the growth of the market in North America.

In September 2016, NeoTract, Inc. (NeoTract) announced that the company has received the de novo approval from USFDA for its UroLife system for prostate implant.

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.


P&S Intelligence

Toll-free: +1-888-778-7886 (USA/Canada)

International: +1-347-960-6455



Connect with us: LinkedIn | Twitter | Google + | Facebook